Total Funding
73
69
Total FundingSeries B raised
Growth Score
-5 pts
Heat Score
-9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
26094
Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy.
Sara Prickett: Chief Operating Officer and Co-Founder- Pascal Hickey: Chief Executive OfficerPast Role: NIOX, Vice President of Early Development
About the Company
Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy.
The company is using their proprietary technology to reset the immune system to tolerate peanut without evoking allergic reactions during treatment.
Aravax was founded in May 2015 through acquisition of
intellectual property developed by Alfred Health and Monash University. Aravax has its headquarters in Melbourne, Australia.
